Sep 05, 2025
REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS II
Aug 18, 2025
REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II
Aug 07, 2025
REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights
Aug 07, 2025
REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy
Jul 31, 2025
REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights
Jun 05, 2025
REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202
May 12, 2025
REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights
May 08, 2025
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting
May 06, 2025
REGENXBIO to Participate in Upcoming Investor Conferences
Mar 13, 2025
REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates
Mar 04, 2025
REGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS Diseases
Feb 26, 2025
REGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights
Jan 30, 2025
REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025
Jan 13, 2025
AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program
Nov 14, 2024
REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202
Nov 06, 2024
REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates
Oct 30, 2024
REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights
Oct 21, 2024
REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024
Oct 18, 2024
REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting
Sep 17, 2024
REGENXBIO Appoints Mitchell Chan as Chief Financial Officer